Post Blogs, Photos, Youtube, Vimeo Videos, Topics, Events, Groups.
+ Larger Font | - Smaller Font

Welcome to Robins Social Network

Be part of the community and join us today!

More than 100 subcutaneous biologics have been approved and over 350 such drug candidates are being evaluated in the clinical stages of development, for the treatment of a wide variety of disease indications, claims Roots Analysis

Several approved therapeutic products, which are currently available as intravenous dosage forms, are being reformulated and evaluated for subcutaneous administration. Further, many existing drug delivery devices, including prefilled syringes, pen injectors, autoinjectors, needle-free injectors and large volume wearable injectors, have been / are being designed for subcutaneous administration of biologics.


To order this 530+ page report, which features 160+ figures and 190+ tables, please visit this link


The USD 180+ billion (by 2030) financial opportunity associated with subcutaneous biologics, affiliated drug delivery systems and subcutaneous formulation technology licensing deals, has been analyzed across the following segments:

§  Phase of development

§  Approved

§  Pre-registration & Phase III

§  Phase II & Phase II/III


§  Type of molecule

§  Cell and gene therapies

§  Monoclonal antibodies

§  Proteins

§  Peptides (recombinant)

§  Vaccines

§  Others


§  Target therapeutic area

§  Autoimmune disorders

§  Blood disorders

§  Bone disorders

§  Genetic disorders

§  Metabolic disorders

§  Neurological disorders

§  Oncological disorders

§  Respiratory disorders

§  Others


§  Type of drug delivery system

§   Large volume wearable injectors

§   Autoinjectors

§   Prefilled syringes

§   Needle-free injectors

§   Drug reconstitution systems


§  Revenues from licensing deals

§   Upfront payments

§   Milestone payments


§  Key geographical regions

§   North America

§   Europe

§   Asia Pacific

§   Rest of the World


The Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030report features the following companies, which we identified to be key players in this domain:

§  Adocia

§  Ajinomoto Bio-Pharma Services

§  Arecor

§  Alteogen

§  Ascendis Pharma

§  Avadel Pharmaceuticals

§  Camurus

§  Creative BioMart

§  Creative Biolabs


§  Eagle Pharmaceuticals

§  Halozyme Therapeutics

§  MedinCell

§  Xeris Pharmaceuticals

§  Serina Therapeutics


Table of Contents

1.     Preface


2.     Executive Summary


3.     Introduction


4.     Subcutaneous Biologics: Current Market Landscape


5.     Case Study: Leading Subcutaneous Biologics


6.     Subcutaneous Formulation Technologies: Current Market Landscape


7.     Subcutaneous Formulation Technology Developers: Company Competitiveness Analysis


8.     Subcutaneous Formulation Technology Developers: Company Profiles


9.     Partnerships and Collaborations


10.  Subcutaneous Drug Delivery Systems: Current Market Landscape


11.  Swot Analysis


12.  Market Forecast and Opportunity Analysis


13.  Concluding Remarks


14.  Executive Insights


15.  Appendix 1:  Tabulated Data


16.  Appendix 2: List Of Companies And Organization



To purchase a copy, please visit


Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

+44 (122) 391 1091


on January 6 at 9:49

Comments (0)

Become a member and experience a unique opportunity to post blogs, photos, Youtube Vimeo videos, topics, events, and create groups on Robin's Social Networking Site. Use Robin's Social to sell products, services and market your business when posting blogs.

By registering and posting content, you agree to the terms listed at... Posting Terms and Conditions. Enjoy!

© 2022 Content By Members. All Rights Reserved.